Skip to content

The effect of DPMAS treatment on the blood concentration of voriconazole in patients with liver failure and an exploration of individualized regimen

The effect of DPMAS treatment on the blood concentration of voriconazole in patients with liver failure and an exploration of individualized regimen

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094658
Enrollment
Unknown
Registered
2024-12-25
Start date
2025-01-23
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver failure

Interventions

patients with liver failure:None

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.(1)Aged 18 to 70 years (inclusive); 2.(2) Chronic liver disease, regardless of etiology; 3.(3) Meet the diagnostic criteria of the Asia-Pacific Guidelines for Acute-on-chronic Liver Failure: extreme fatigue, obvious gastrointestinal symptoms; PTA =40% or INR =1.5; rapidly deepening jaundice, serum TBil =85µmol/L with or without complications such as hepatic encephalopathy, ascites, hepatorenal syndrome, etc. 4.(4) Patients with confirmed, clinically diagnosed, or suspected invasive fungal infection; 5.(5) Continuous use of voriconazole for more than 3 days; 6.(6) Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age); 7.(7) Willing to receive treatment and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.(1)Pregnant women; 2.(2) Untreated HIV infection; 3.(3) Patients with other chronic end-stage organ failure; 4.(4) Patients with advanced malignant tumors; 5.(5) Patients with intolerance or poor compliance; 6.(6) Patients who are unable or unwilling to provide informed consent or follow the requirements of the study; 7.(7) Patients with a history of allergy to voriconazole and in addition to the above exclusion criteria, patients who meet any of the contraindications in the experimental drug instructions;

Design outcomes

Primary

MeasureTime frame
Plasma voriconazole concentrations in patients 0-30 minutes after asunaprevirDPMAS treatment;Drug dosage for DPMAS treatment of wastewater;The Cmin of voriconazole on the second day of DPMAS treatment was calculated, and the difference between the measured Cmin and the Cmin simulated by the Monte Carlo curve was calculated;

Countries

China

Contacts

Public ContactTaotao Yan

The First Affiliated Hospital of Xi'an Jiaotong University

yantaotao123@xjtu.edu.cn+86 29 85323262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026